Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDI-PHYSICS' NEW CYCLOTRON WILL PRODUCE I-123 RADIOISOTOPE

Executive Summary

MEDI-PHYSICS' NEW CYCLOTRON WILL PRODUCE I-123 RADIOISOTOPE for use in radiopharmaceuticals at six times the rate of the subsidiary's four other cyclotrons, the firm said in a Nov. 9 press release. Total project cost of installing the 144-tone particle accelerator is approximately $10 mil. The 70 mil. electron volt cyclotron will begin operating at full capacity in its Arlington Heights, Illinois site next June, Medi-Physics' said. The newly installed cyclotron will supply the I-123 radioisotope used in Medi-Physics' brain imaging agent, Perfusamine. An NDA for the agent is pending at FDA. Perfusamine clinical trials began at 10 sites in January 1983. Indicated for use as an imaging agent for the study of brain perfusion, Perfusamine "should be extremely helpful in the early detection of stroke caused by blockage," the company said. Medi-Physics noted that Perfusamine also may prove useful in diagnosing epilepsy and mental disorders associated with abnormal brain perfusion, such as Alzheimer's disease. A panel date has not yet been set for FDA review of the radiopharmaceutical. In addition to its use as a key ingredients in the brain imaging agent, the I-123 produced by the new cyclotron will "have the potential" for use in Medi-Physics' already-approved kidney imaging agent, Nephroflow. However, Medi-Physics noted that since I-123 produced at the new site will be purer than the radioisotope currently used in Nephroflow, FDA may require additional clinical data. Medi-Physics added that a heart imaging radiopharmaceutical which employs I-123 currently is under research and development at the firm.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel